Compass Therapeutics Inc. - Asset Resilience Ratio
Compass Therapeutics Inc. (CMPX) has an Asset Resilience Ratio of 75.94% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how liquid is Compass Therapeutics Inc.'s working capital to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2025)
This chart shows how Compass Therapeutics Inc.'s Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see CMPX current and non-current assets.
Liquid Assets Composition Over Time
This chart breaks down Compass Therapeutics Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read CMPX total debt and obligations for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $144.43 Million | 75.94% |
| Total Liquid Assets | $144.43 Million | 75.94% |
Asset Resilience Insights
- Very High Liquidity: Compass Therapeutics Inc. maintains exceptional liquid asset reserves at 75.94% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Compass Therapeutics Inc. Industry Peers by Asset Resilience Ratio
Compare Compass Therapeutics Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH |
Biotechnology | 33.23% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
Annual Asset Resilience Ratio for Compass Therapeutics Inc. (2021–2025)
The table below shows the annual Asset Resilience Ratio data for Compass Therapeutics Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 81.18% | $178.26 Million | $219.59 Million | +21.89pp |
| 2024-12-31 | 59.29% | $83.24 Million | $140.40 Million | -22.46pp |
| 2023-12-31 | 81.74% | $128.23 Million | $156.88 Million | +5.78pp |
| 2022-12-31 | 75.97% | $151.66 Million | $199.65 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $153.76 Million | -- |
About Compass Therapeutics Inc.
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tum… Read more